{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:47:57Z","timestamp":1792759677508,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114150","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T16:06:57Z","timestamp":1643386017000},"page":"114150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist"],"prefix":"10.1016","volume":"231","author":[{"given":"Xiong","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-7511","authenticated-orcid":false,"given":"Huijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-5950","authenticated-orcid":false,"given":"Xiao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Schooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ciechanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114150_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/382829a0","article-title":"The lymphocyte chemoattractant SDF-1 is a ligand for LESTR\/fusin and blocks HIV-1 entry","volume":"382","author":"Bleul","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114150_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114150_bib3","doi-asserted-by":"crossref","first-page":"15566","DOI":"10.1074\/jbc.M110.103408","article-title":"CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin","volume":"285","author":"Saini","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nm1567","article-title":"MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment","volume":"13","author":"Bernhagen","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114150_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/geno.1995.1180","article-title":"Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene","volume":"28","author":"Shirozu","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2022.114150_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2217\/fon.13.193","article-title":"CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis","volume":"10","author":"Shi","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2022.114150_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fimmu.2015.00429","article-title":"Diversity and inter-connections in the CXCR4 chemokine receptor\/ligand family: molecular perspectives","volume":"6","author":"Pawig","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2022.114150_bib8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/jm200568c","article-title":"Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4)","volume":"55","author":"Choi","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib9","doi-asserted-by":"crossref","first-page":"eaat2214","DOI":"10.1126\/scisignal.aat2214","article-title":"Biased antagonism of CXCR4 avoids antagonist tolerance","volume":"11","author":"Hitchinson","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2022.114150_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114150_bib11","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/sj.leu.2402684","article-title":"The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD\/SCID and NOD\/SCID\/B2mnull mice","volume":"16","author":"Lapidot","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114150_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2022.114150_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/stem.2054","article-title":"Concise review: CXCR4\/CXCL12 signaling in immature hematopoiesis-lessons from pharmacological and genetic models","volume":"33","author":"Karpova","year":"2015","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2022.114150_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114150_bib15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","volume":"109","author":"Spoo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114150_bib16","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1535-7163.MCT-06-0228","article-title":"Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias","volume":"5","author":"Zeng","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114150_bib17","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A\u00a0phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114150_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A\u00a0review on CXCR4\/CXCL12 axis in oncology: No place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114150_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114150_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2022.114150_bib21","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114150_bib22","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1096\/fj.201802067RR","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1\u2013PD-L1 pathways prolongs survival of ovarian tumor\u2013bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2022.114150_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/bbrc.1999.1476","article-title":"Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide","volume":"264","author":"Luo","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114150_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1006\/bbrc.1999.1441","article-title":"The role of positively charged residues in CXCR4 recognition probed with synthetic peptides","volume":"263","author":"Luo","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114150_bib25","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1021\/bi992750v","article-title":"A\u00a0novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II","volume":"39","author":"Zhou","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114150_bib26","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.1021\/bi000633q","article-title":"Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II","volume":"39","author":"Luo","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114150_bib27","doi-asserted-by":"crossref","first-page":"17476","DOI":"10.1074\/jbc.M202063200","article-title":"Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines","volume":"277","author":"Zhou","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib28","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1128\/JVI.79.24.15398-15404.2005","article-title":"Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors","volume":"79","author":"Choi","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2022.114150_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chembiol.2005.10.012","article-title":"SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development","volume":"13","author":"Kumar","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114150_bib30","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1074\/jbc.M611599200","article-title":"Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines","volume":"282","author":"Choi","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib31","doi-asserted-by":"crossref","first-page":"11489","DOI":"10.1128\/JVI.02845-06","article-title":"Crystal structure and structural mechanism of a novel anti-human immunodeficiency virus and D-amino acid-containing chemokine","volume":"81","author":"Liu","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2022.114150_bib32","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1021\/bi2016712","article-title":"A\u00a0novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry","volume":"51","author":"Choi","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114150_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbrc.2013.05.038","article-title":"A\u00a0synthetic bivalent ligand of CXCR4 inhibits HIV infection","volume":"435","author":"Xu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114150_bib34","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1016\/j.bmc.2016.08.062","article-title":"J.\u00a0An, Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4","volume":"24","author":"Yang","year":"2016","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/0963689718784957","article-title":"Novel bivalent and D-peptide ligands of CXCR4 mobilize hematopoietic progenitor cells to the blood in C3H\/HeJ mice","volume":"27","author":"Mao","year":"2018","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejmech.2022.114150_bib36","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.16127","article-title":"A\u00a0novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches","volume":"187","author":"Huang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.114150_bib37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejmech.2019.03.056","article-title":"High affinity CXCR4 inhibitors generated by linking low affinity peptides","volume":"172","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib38","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1021\/acs.jmedchem.8b00450","article-title":"Design, synthesis, and pharmacological evaluation of second-generation tetrahydroisoquinoline-based CXCR4 antagonists with favorable ADME properties","volume":"61","author":"Nguyen","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acs.jmedchem.7b01322","article-title":"Development of stem-cell-mobilizing agents targeting CXCR4 receptor for peripheral blood stem cell transplantation and beyond","volume":"61","author":"Wu","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114150_bib41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1126\/science.1261064","article-title":"Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine","volume":"347","author":"Qin","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114150_bib42","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1021\/acs.jmedchem.6b01309","article-title":"Structural analysis of chemokine receptor\u2013ligand interactions","volume":"60","author":"Arimont","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-1107-2","article-title":"Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial","volume":"15","author":"Karpova","year":"2017","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114150_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2015-02-628677","article-title":"Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy","volume":"126","author":"Cho","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114150_bib45","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114150_bib46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bcp.2009.06.010","article-title":"Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4","volume":"78","author":"Bodart","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114150_bib47","article-title":"Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist","volume":"57","author":"Schols","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114150_bib48","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1021\/acs.jmedchem.5b00987","article-title":"Probing the molecular interactions between CXC chemokine receptor 4 (CXCR4) and an arginine-based tripeptidomimetic antagonist (KRH-1636)","volume":"58","author":"Zachariassen","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib49","doi-asserted-by":"crossref","first-page":"112410","DOI":"10.1016\/j.ejmech.2020.112410","article-title":"Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists","volume":"200","author":"Fang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib50","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1073\/pnas.0630420100","article-title":"A\u00a0duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity","volume":"100","author":"Ichiyama","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114150_bib51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bcp.2005.05.035","article-title":"AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor","volume":"70","author":"Hatse","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114150_bib52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd2819","volume":"8","author":"DiPersio","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114150_bib53","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1073\/pnas.94.9.4653","article-title":"A\u00a0new reporter cell line to monitor HIV infection and drug susceptibility in\u00a0vitro","volume":"94","author":"Gervaix","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114150_bib54","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.3390\/molecules23113036","article-title":"J.\u00a0An, virtual screening, biological evaluation, and 3D-QSAR studies of new HIV-1 entry inhibitors that function via the CD4 primary receptor","volume":"23","author":"Zhang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114150_bib55","doi-asserted-by":"crossref","first-page":"23736","DOI":"10.1074\/jbc.M000776200","article-title":"Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities","volume":"275","author":"Brelot","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib56","doi-asserted-by":"crossref","first-page":"42826","DOI":"10.1074\/jbc.M106582200","article-title":"Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies","volume":"276","author":"Zhou","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib57","doi-asserted-by":"crossref","first-page":"12667","DOI":"10.1128\/JVI.79.20.12667-12673.2005","article-title":"Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1 alpha on CXCR4 transmembrane helical domains","volume":"79","author":"Tian","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2022.114150_bib58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0092-8674(00)81393-8","article-title":"CD4-independent infection by HIV-2 is mediated by fusin\/CXCR4","volume":"87","author":"Endres","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114150_bib59","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/jvi.71.6.4744-4751.1997","article-title":"Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity","volume":"71","author":"Brelot","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2022.114150_bib60","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1111\/bph.12842","article-title":"Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis","volume":"171","author":"Thiele","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114150_bib61","doi-asserted-by":"crossref","first-page":"D356","DOI":"10.1093\/nar\/gkv1178","article-title":"GPCRdb: an information system for G protein-coupled receptors","volume":"44","author":"Isberg","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2022.114150_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1875397301004010084","article-title":"Luciferase reporter assay system for deciphering GPCR pathways","volume":"4","author":"Cheng","year":"2010","journal-title":"Curr. Chem. Genom."},{"key":"10.1016\/j.ejmech.2022.114150_bib63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00018-004-4462-3","article-title":"G-protein signaling: back to the future","volume":"62","author":"McCudden","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2022.114150_bib64","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114150_bib65","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2002221","article-title":"A\u00a0synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells","volume":"4","author":"Yagi","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2022.114150_bib66","doi-asserted-by":"crossref","first-page":"G844","DOI":"10.1152\/ajpgi.00112.2003","article-title":"SDF-1\/CXCL12 regulates cAMP production and ion transport in intestinal epithelial cells via CXCR4","volume":"286","author":"Dwinell","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2022.114150_bib67","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/med.21464","article-title":"Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology","volume":"38","author":"Tsou","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114150_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acsmedchemlett.8b00441","article-title":"Tetrahydroisoquinoline CXCR4 antagonists adopt a hybrid binding mode within the peptide subpocket of the CXCR4 receptor","volume":"10","author":"Katzman","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114150_bib69","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1074\/jbc.M309546200","article-title":"Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor","volume":"279","author":"Rosenkilde","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114150_bib70","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/mol.108.049775","article-title":"Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors","volume":"74","author":"Wong","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114150_bib71","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbic.201402056","article-title":"Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure","volume":"15","author":"Cox","year":"2014","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2022.114150_bib72","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41467-018-05035-5","article-title":"Peptide density targets and impedes triple negative breast cancer metastasis","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:37:45Z","timestamp":1759329465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":72,"alternative-id":["S0223523422000526"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114150","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114150"}}